Pfizer Stock Leads 3 AI Healthcare Names Worth Further Research

Artificial intelligence in healthcare is attracting fresh attention as investors weigh inflation trends, shifting interest rate expectations, and volatile energy costs across major economies. While higher yields and mixed growth signals are reshaping risk appetite, AI Healthcare Stocks sit at the intersection of cost pressure and the search for better outcomes, using data to support diagnostics, treatment decisions, and efficiency. The Transformative AI Healthcare Stocks screener focuses on companies tied to these structural shifts, rather than short term macro moves. In this article, you will see 3 of the best stocks from the screener that stand out for further research.

Pfizer (PFE)

Overview: Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells prescription medicines and vaccines across areas such as cardiovascular disease, migraine, rare diseases, oncology, inflammation, and infectious diseases, including COVID 19 treatments. It also partners with other drug makers and is pushing into biomolecular AI to support its research and development.

Operations: Pfizer generates about US$61.9b in revenue mainly from its Global Biopharmaceuticals Business, with around US$37.4b coming from the United States and the rest split between developed and emerging markets.

Market Cap: US$143.3b

Pfizer offers investors a large, diversified pharmaceutical portfolio and a deep late stage pipeline in oncology, rare diseases, vaccines, and obesity treatments, while also leaning into AI to make drug development faster and more efficient. At the same time, the company is dealing with earnings pressure, a high dividend that is not fully covered by cash flows, and a heavy reliance on external funding, all of which raise financial risk. Add in patent cliffs, active mRNA patent litigation, and a one off US$10.7b loss, and investors face a complex mix of potential reward and real uncertainty that may warrant closer attention when considering whether Pfizer suits a given portfolio.

Pfizer’s AI initiatives and broad drug portfolio may be obscuring a different story about its dividend pressures and funding needs. Before you decide where it fits in your portfolio, review the 1 key reward and 4 important warning signs (3 are major!)

Tempus AI (TEM)

Overview: Tempus AI is a healthcare technology company that links genomic testing, clinical records, imaging, and AI tools into a single data platform that helps doctors tailor treatment and helps drug companies run faster, more targeted research. Its products range from lab tests and clinical software at the hospital level to data access and AI applications for life sciences companies, all built around a large, growing library of de-identified patient data.

Operations: Tempus AI generates about US$1.4b in revenue from Medical Labs & Research services in the United States.

Market Cap: US$9.6b

Tempus AI sits at the heart of AI driven healthcare, with tens of millions of de-identified patient records, hundreds of petabytes of data, and products already used by most of the largest biopharma companies, which together create a data moat that is hard for rivals to replicate. The higher margin Data and Applications segment is becoming more important, adjusted operating losses have narrowed, and recent product launches such as the next generation Lens platform and FDA validated AI models show how that dataset can feed new tools. At the same time, the stock carries meaningful risk, including ongoing losses, heavy reliance on debt funding, and recent insider selling alongside high executive pay. Investors who want to understand whether the trade off between growth potential and financial risk suits their portfolio may need to look closer at how Tempus is priced and funded, and what would need to go right for the thesis to play out.

Tempus AI’s growing data moat and narrowing losses hint at a story that may be more about transition than early stage risk, so it could be worth reviewing the full 2 key rewards and 2 important warning signs

Medtronic (MDT)

Overview: Medtronic is a global medical technology company that supplies devices and systems for heart and blood vessel disease, brain and spine disorders, chronic pain, and surgical care, as well as diabetes management tools such as insulin pumps and continuous glucose monitors.

Operations: Medtronic generates about US$39.4b in revenue, led by Cardiovascular at US$14.0b, Neuroscience at US$10.3b, Medical Surgical at US$8.8b, and Other at US$3.2b, with sales split fairly evenly between the United States at US$18.1b and the rest of the world at US$18.1b.

Market Cap: US$107.0b

Medtronic offers exposure to AI powered surgical platforms, robotics, and neuromodulation in a single large cap device company, while trading on a lower P/E than many US medical equipment peers. Recent moves such as the US$650m SPR Therapeutics acquisition and the ICU partnership with Apollo Hospitals illustrate how Medtronic is focusing on pain management and data rich critical care, even as some segments and margins come under pressure and revenue growth trails the wider market. With a 3.41% dividend yield and a board and management team described as experienced, the company presents a mix of income, restructuring, and new product risk for investors who are comfortable with slower growth and execution questions around diabetes and next generation platforms.

Medtronic’s mix of AI powered surgery, robotics, and a 3.41% dividend yield hints at a story where income and technology are starting to intersect, so it is worth scanning the analyst forecasts for Medtronic to see what might shift that balance next.

The three AI healthcare stocks in this article are only a starting point, and the full Transformative Artificial intelligence (AI) Healthcare Stocks screener surfaces 36 more companies with equally compelling narratives through the Transformative Artificial intelligence (AI) Healthcare Stocks screener. Identify and analyze the exact catalysts that matter to you, from diagnostic accuracy and personalized medicine to workflow automation and telehealth scale. This can help you focus on the highest conviction opportunities in this space.

Take Control of Your Investment Journey

If Pfizer or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Alternatives Before Everyone Else?

Fresh stock ideas can move from quiet to flying once attention hits. Use the window while it matters, before the crowd catches on and get in early.

• Spot companies building momentum in smaller corners of the market by scanning the 20 high quality undiscovered gems curated for quality and strong underlying fundamentals.
• Track where resilient cash flows meet stronger balance sheets and filter the noise using the list of solid balance sheet and fundamentals (47 results) crafted to highlight financial strength first.
• Lean into structural shifts in power and infrastructure by running the 33 power grid technology and infrastructure stocks for companies tied to long term grid and electrification projects.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com